KBC Group NV Boosts Position in Hologic, Inc. (NASDAQ:HOLX)

KBC Group NV boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 93,376 shares of the medical equipment provider’s stock after purchasing an additional 5,747 shares during the period. KBC Group NV’s holdings in Hologic were worth $6,731,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. Prentiss Smith & Co. Inc. lifted its holdings in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after acquiring an additional 130 shares during the last quarter. Covestor Ltd lifted its stake in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 145 shares during the last quarter. Finally, Empirical Finance LLC raised its holdings in shares of Hologic by 1.8% in the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after buying an additional 147 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.88% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research analyst reports. Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Morgan Stanley lowered their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Up 1.1 %

HOLX opened at $72.17 on Friday. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The stock has a fifty day moving average price of $73.49 and a 200-day moving average price of $78.11. The firm has a market cap of $16.29 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 2.43 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the firm posted $0.89 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.